JPWO2021092056A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021092056A5 JPWO2021092056A5 JP2022525788A JP2022525788A JPWO2021092056A5 JP WO2021092056 A5 JPWO2021092056 A5 JP WO2021092056A5 JP 2022525788 A JP2022525788 A JP 2022525788A JP 2022525788 A JP2022525788 A JP 2022525788A JP WO2021092056 A5 JPWO2021092056 A5 JP WO2021092056A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- bispecific antibody
- maintenance dose
- pharmaceutical composition
- maintenance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207293 | 2019-11-05 | ||
| EP19207293.2 | 2019-11-05 | ||
| EP20179573.9 | 2020-06-11 | ||
| EP20179573 | 2020-06-11 | ||
| PCT/US2020/058939 WO2021092056A1 (fr) | 2019-11-05 | 2020-11-04 | Méthodes de traitement avec des anticorps contre bcma et cd3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553822A JP2022553822A (ja) | 2022-12-26 |
| JPWO2021092056A5 true JPWO2021092056A5 (fr) | 2023-11-13 |
Family
ID=75849140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525788A Pending JP2022553822A (ja) | 2019-11-05 | 2020-11-04 | Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230057602A1 (fr) |
| EP (1) | EP4054725A4 (fr) |
| JP (1) | JP2022553822A (fr) |
| KR (1) | KR20220093141A (fr) |
| CN (1) | CN115279459A (fr) |
| AU (1) | AU2020379757A1 (fr) |
| BR (1) | BR112022008516A2 (fr) |
| CA (1) | CA3160137A1 (fr) |
| IL (1) | IL292704A (fr) |
| MX (1) | MX2022005292A (fr) |
| WO (1) | WO2021092056A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963692A1 (fr) | 2014-10-09 | 2016-04-14 | Engmab Ag | Anticorps bispecifiques contre cd3epsilon et ror1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009299794B2 (en) * | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| US10683369B2 (en) * | 2015-08-03 | 2020-06-16 | Engmab Sàrl | Monoclonal antibodies against BCMA |
| CN110167964B (zh) * | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
-
2020
- 2020-11-04 JP JP2022525788A patent/JP2022553822A/ja active Pending
- 2020-11-04 MX MX2022005292A patent/MX2022005292A/es unknown
- 2020-11-04 BR BR112022008516A patent/BR112022008516A2/pt unknown
- 2020-11-04 IL IL292704A patent/IL292704A/en unknown
- 2020-11-04 CA CA3160137A patent/CA3160137A1/fr active Pending
- 2020-11-04 EP EP20884171.8A patent/EP4054725A4/fr active Pending
- 2020-11-04 AU AU2020379757A patent/AU2020379757A1/en active Pending
- 2020-11-04 CN CN202080091830.3A patent/CN115279459A/zh active Pending
- 2020-11-04 US US17/772,865 patent/US20230057602A1/en active Pending
- 2020-11-04 WO PCT/US2020/058939 patent/WO2021092056A1/fr unknown
- 2020-11-04 KR KR1020227017380A patent/KR20220093141A/ko unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6189491B2 (ja) | Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防 | |
| Aukrust et al. | Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo | |
| US9308256B2 (en) | Method of treating rheumatoid arthritis with an anti-IL-6R antibody | |
| JP2014114288A5 (fr) | ||
| US20220249659A1 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| WO2020261093A1 (fr) | Schéma posologique et polythérapies pour des anticorps multispécifiques ciblant un antigène de maturation des lymphocytes b | |
| JP2005506331A5 (fr) | ||
| CN114206346A (zh) | 施用嵌合抗原受体免疫疗法的方法 | |
| US20210253713A1 (en) | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use | |
| JP2021167324A5 (fr) | ||
| IL292704A (en) | Methods of treatment with antibodies against bcma and cd3 | |
| KR20220141306A (ko) | 자가면역 질환의 항-bcma 요법(anti-bcma therapy in autoimmune disorders) | |
| TW201322985A (zh) | 由ＥｐＣＡＭｘＣＤ３雙特異性抗體引起之不良作用的預防 | |
| JPWO2021092056A5 (fr) | ||
| JPWO2021224499A5 (fr) | ||
| JP2022530599A (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| JP2023524068A (ja) | サイトカイン関連有害事象を治療する方法 | |
| JPWO2021123902A5 (fr) | ||
| Könemann et al. | Cardiac immunomodulation | |
| JP2021506817A5 (fr) | ||
| Ochi et al. | Bispecific antibodies for multiple myeloma: past, present and future | |
| US20230416412A1 (en) | Prevention or mitigation of t-cell engaging agent-related adverse effects | |
| JPWO2019186369A5 (fr) | ||
| RU2022101306A (ru) | Схема введения доз и виды комбинированной терапии для полиспецифических антител, нацеленных на антиген созревания в-клеток | |
| NZ791361B2 (en) | Engineered anti-il-2 antibodies |